What's new
This page lists items that we have published for the first time or updated in the last 7, 30 or 60 days. Use the filters to narrow results by audience, product type, content type or topic.
You can also stay informed by:
- subscribing to our updates to receive same-day notification emails on safety information, scheduling updates or media releases.
- checking for open consultations.
- joining any upcoming events.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (6)
- Breast implant hub (1)
- Clinical trials (1)
- Committees and advisory bodies (15)
- Compliance and enforcement (5)
- Cosmetics (1)
- COVID-19 (1)
- Import and export (2)
- Labelling and packaging (1)
- Legislation (1)
- Manufacturing (2)
- Metal-on-metal hip replacement implants hub (1)
- Safety monitoring and information (10)
- Scheduling (national classification system) (7)
- Shortages and supply disruptions (11)
- Sunscreens (6)
- Unique Device Identification (UDI) hub (7)
- Urogynaecological (transvaginal) surgical mesh hub (1)
- Vaping hub (2)
What's new
99 result(s) found, displaying 1 to 25
-
Media releasesWe have issued 2 infringement notices totalling $37,560 to Booty N Buff Nutrition Caringbah Pty Ltd (Booty N Buff Nutrition) for the alleged unlawful advertising of therapeutic goods in contravention of the Therapeutic Goods Act 1989 (the Act).
-
-
PageCheck this page for key information and updates on the Trulicity shortage.
-
Market actionsKmart Australia Ltd is recalling their Anko Small Gel Pak and Anko Large Gel Pak because they contain ethylene glycol, a toxic substance.
-
PageSerious Scarcity Substitution Instruments (SSSIs) allow community pharmacists to substitute specific medicines without prior approval from the prescriber so long as the permitted circumstances within the SSSI are met.
-
News articlesOn 17 December 2025, the TGA made the decision to approve the registration of lenacapavir (YEYTUO).
-
Advertising permissionThis instrument is made under section 42DK of the Therapeutic Goods Act 1989
-
PageThe ARGOM will help you navigate the regulatory requirements for over-the-counter (OTC) medicines in Australia.
-
ChecklistsThis checklist assists sponsors to prepare a change application at the C1 level for a registered OTC medicine.
-
PageThe Freedom of Information disclosure log gives access to information we've released in response to an FOI request.
-
PageFor health professionals. Links to fact sheets and other resources about urogynaecological (transvaginal) surgical mesh.
-
Australian public assessment report (AusPar)Sondelbay, Teriparintas and Teriparaccord have been approved for the treatment of osteoporosis.
-
PageUrogynecological mesh (transvaginal) support groups and services.
-
PageThe EU MDR Transition web publication service provides notifications to providers and consumers going through low-risk changes, as part of the transition.
-
-
PageKey information about the shortage for patients, carers and health care professionals
-
Meeting statementsOverview of the meeting to discuss proposed changes to the Authorised Prescriber application process
-
News articlesWe have updated the rules for lawfully handling vaping products in Australia. These changes make it clearer for businesses that need to lawfully possess and supply vaping goods as part of their operations.
-
PageSearch the prescribing medicines in pregnancy database.
-
DatasetSearch approvals to import and supply medicines not in the ARTG to address medicine shortages.
-
News articlesThe Prescription Medicines in Pregnancy database has been updated to include new entries.
-
ServiceAs a medical practitioner, you can apply to access an unapproved therapeutic good for a class of patients with the same condition.
-
Prescription medicine decision summaryAlyftrek (vanzacaftor, tezacaftor, deutivacaftor) has been approved to treat people with cystic fibrosis who are 6 years and older. It has 3 active ingredients that target the genetic cause of cystic fibrosis.
-
GuidanceGuidance for medical practitioners, Human Research Ethics Committees, specialist colleges and sponsors of 'unapproved' therapeutic goods.
-
DatasetSearch our database of sponsor-requested cancellations from the Australian Register of Therapeutic Goods (ARTG).